426 reports of this reaction
3.1% of all METHIMAZOLE reports
#3 most reported adverse reaction
FATIGUE is the #3 most commonly reported adverse reaction for METHIMAZOLE, manufactured by AiPing Pharmaceutical, Inc.. There are 426 FDA adverse event reports linking METHIMAZOLE to FATIGUE. This represents approximately 3.1% of all 13,542 adverse event reports for this drug.
Patients taking METHIMAZOLE who experience fatigue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FATIGUE is moderately reported among METHIMAZOLE users, representing a notable but not dominant share of adverse events.
In addition to fatigue, the following adverse reactions have been reported for METHIMAZOLE:
The following drugs have also been linked to fatigue in FDA adverse event reports:
FATIGUE has been reported as an adverse event in 426 FDA reports for METHIMAZOLE. This does not prove causation, but indicates an association observed in post-market surveillance data.
FATIGUE accounts for approximately 3.1% of all adverse event reports for METHIMAZOLE, making it one of the most commonly reported side effect.
If you experience fatigue while taking METHIMAZOLE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.